title: Drug Survival Analysis Is Not a Good Method for Assessing the Safety or Effectiveness of Systemic Therapies in Psoriasis.
authors.affiliation: Servicio de Dermatología, Hospital Universitario de Umeå, Umeå, Suecia; Unidad de Investigación, Fundación Academia Española de Dermatología y Venereología, Madrid, España. Electronic address: pauladavilaseijo@gmail.com.
authors.forename: P
authors.initials: P
authors.lastname: Dávila-Seijo
authors.affiliation: Unidad de Investigación, Fundación Academia Española de Dermatología y Venereología, Madrid, España; Servicio de Dermatología, Complexo Hospitalario Universitario de Vigo, Vigo, Pontevedra, España.
authors.forename: I
authors.initials: I
authors.lastname: García-Doval
mesh_terms: D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D001685:Biological Factors / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D015415:Biomarkers; D004334:Drug Administration Schedule; D016527:Drug Costs; D004341:Drug Evaluation / Q000379:methods* / Q000706:statistics & numerical data; D057915:Drug Substitution; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D017063:Outcome Assessment, Health Care / Q000379:methods* / Q000706:statistics & numerical data; D011565:Psoriasis / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D018501:Antirheumatic Agents; D001685:Biological Factors; D015415:Biomarkers; D007166:Immunosuppressive Agents